Related Experiment Video
Updated: Jun 13, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Rituximab (Rituxan)
David T Selewski1, G V Shah, R J Mody
1Division of Pediatric Nephrology, University of Michigan Mott Children's Hospital, Ann Arbor, Michigan, USA. dselewsk@med.umich.edu
Abstract:
Rituximab is a monoclonal antibody that was first approved by the FDA as an antineoplastic agent designed to treat B-cell malignancies. This article will review the mechanism of action and clinical role of this anti-B-cell agent.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Respiratory Syncytial Virus Disease
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Tumor Immunotherapy
Rheumatic Heart Disease III: Medical Management

